Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (NASDAQ: VVOS) announced that founder and CEO R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference at The Westin New York Grand Central in New York City on September 9, 2026, at 8:45 a.m. Eastern Time. Management will also hold a Q&A session and be available for one-on-one meetings with institutional investors during the conference.
Vivos Therapeutics (Nasdaq: VVOS) signed definitive collaboration and operating agreements with South Palm Cardiovascular Associates (SPCVA) to establish and operate a regional Sleep & Airway Medicine Center (SAMC) in Palm Beach County, Florida, through a new management services organization, AIM Florida.
According to Vivos, it expects to hold a 75% majority membership and economic interest in AIM Florida, subject to regulatory and contractual terms. The parties are evaluating locations and negotiating a lease, with patient treatment and revenue generation targeted for the first quarter of 2027, pending customary startup milestones.
The initial Sleep Optimization Team is planned to serve about 250 patients per month and, based on Vivos’ Las Vegas experience and current assumptions, could generate up to $6 million in annual revenue with contribution margins of 30% or more once fully deployed. SPCVA, a cardiology practice with approximately 30,000 patients, is expected to help build referrals for comprehensive OSA testing and treatment using Vivos’ FDA‑cleared technologies.
Vivos Therapeutics (Nasdaq: VVOS) reported that average weekly new obstructive sleep apnea patient referrals into its Nevada Sleep & Airway Medicine Centers rose 212% over the past six weeks compared with the prior six weeks. Since June 1, the total average weekly number of referrals has increased nearly five-fold and has continued to grow week over week.
The company will open an 8,100 sq. ft. sleep testing and treatment facility in Henderson, Nevada, on August 27, 2026. According to Vivos, the Henderson practice, previously in a smaller space, achieved its highest total collections in two of the past three months, and the company expects revenue from Henderson operations to grow further once the new facility is fully operational.
Vivos Therapeutics (Nasdaq: VVOS) announced the grand opening of a new state-of-the-art sleep diagnostic, testing, and treatment center in Henderson, Nevada, with the official event scheduled for August 27, 2026. According to Vivos Therapeutics, this full-service facility is expected to more than double annual revenue production capacity in Henderson to over $10 million.
The center, part of the Sleep Centers of Nevada network, is planned to employ up to 30 medical and support staff and offer integrated services including diagnostic testing, clinical evaluation, and multiple FDA-cleared treatment modalities. Vivos reported that incoming referrals in the Las Vegas market have more than doubled since the May–June timeframe, and the added capacity is expected to have an immediate impact on revenue in that market.
Vivos Therapeutics (NASDAQ: VVOS) reported second quarter 2026 revenue of $5.2 million, up 35% year over year, with first-half 2026 revenue of $10.3 million, up 51%. Growth was driven by higher service revenue, mainly from sleep testing and treatment services in Nevada operations.
Gross profit rose to $3.0 million in Q2 and $6.0 million for the first half, with gross margins improving to 57% and 58%, respectively. Operating expenses increased to $7.8 million in Q2 and $17.5 million year-to-date, reflecting the SCN acquisition and new treatment centers. Vivos recorded a Q2 net loss of $5.5 million and a first-half net loss of $13.3 million. As of June 30, 2026, cash and equivalents were $1.8 million, and stockholders’ equity showed a deficit of $3.8 million. Management highlighted rising patient referrals, growing pediatric and insomnia programs, and progress toward partnerships with multi-center cardiology groups in Florida and Arizona.
Vivos Therapeutics (NASDAQ: VVOS) plans to release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time to review results and provide operational updates.
Participants can join the investor call by dialing (800) 717-1738 in the U.S. or (646) 307-1865 internationally. A replay will be available until Friday, August 28, 2026 at (844) 512-2921 or (412) 317-6671 (passcode 1174558). A live webcast and 30-day archive will be accessible at https://vivos.com/investors/. Vivos is a medical technology and healthcare services company focused on FDA-cleared diagnostic and treatment devices for obstructive sleep apnea and related breathing disorders in adults and children.
Vivos Therapeutics (NASDAQ: VVOS) announced an expanded strategic engagement with Greenway Health to deploy Greenway’s AI-by-design Novare platform across Vivos’ clinical and revenue-cycle operations, beginning with Sleep Centers of Nevada (SCN). Greenway’s analysis estimates Novare and related workflow automation could potentially generate about $9.1 million in annual value for Vivos at SCN.
According to Vivos, this includes roughly $8.0 million from increased patient capacity and $1.0 million from revenue-cycle improvements in Nevada, plus up to $1.8 million in annual savings from recovering an estimated 46,000+ labor hours and creating capacity for nearly 30,000 additional patient visits. Vivos plans to extend Novare to new markets in Arizona and Florida, aiming to increase operating leverage by integrating AI-driven clinical documentation, eligibility checks, coding assistance, prior-authorization automation and denial-reduction tools, while limiting growth in administrative headcount.
Vivos Therapeutics (NASDAQ: VVOS) announced that the US Patent and Trademark Office has issued US Patent No. 12,697,190, titled “Vibrational Oral Appliance with Mandibular Advancements.” This continuation of the 2024 foundational Patent No. 12,048,608 broadens protection for the company’s Vivos CARE vibrational oral appliance platform.
The ’190 Patent adds broader, design‑independent claims while the ’608 Patent maintains detailed, structure‑specific coverage, giving Vivos layered intellectual property protection around its core technology. According to Vivos, its CARE oral devices are the only FDA 510(k) cleared oral appliances for treating severe OSA in adults and moderate to severe OSA in children ages 6–17. Studies cited by the company indicate that about 80% of patients treated with Vivos CARE devices achieve significant reductions or complete resolution of OSA symptoms, measured by standard AHI scores. Vivos believes this expanded patent estate strengthens its competitive position in a large, underdiagnosed global sleep apnea market.
Vivos Therapeutics (NASDAQ: VVOS) reported new clinical data on its FDA-cleared Vida® oral appliance for patients with longstanding moderate to severe insomnia.
In a 37-patient single-site study, average Insomnia Severity Index scores fell about 65%, with 100% improving at least one severity level and ending with no or subthreshold insomnia (p≈0.0000001). Vivos sees a potential new insomnia revenue stream, including an estimated $36 million annual addressable market at Sleep Centers of Nevada alone, though it notes the data are early and insomnia-related findings are not FDA-reviewed.
Vivos Therapeutics (NASDAQ: VVOS) extended its strategic financing agreement with Streeterville Capital through August 31, 2026.
Streeterville reaffirmed its commitment to convert up to $4.5 million of debt into a mix of perpetual, non-convertible preferred stock and common stock once Vivos raises $2.6 million, supporting Nasdaq listing compliance and a planned rights offering.